Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89,414,894
-
Number of holders
-
145
-
Total 13F shares, excl. options
-
60,858,590
-
Shares change
-
-188,609
-
Total reported value, excl. options
-
$1,476,104,164
-
Value change
-
+$4,235,576
-
Put/Call ratio
-
70.33%
-
Number of buys
-
73
-
Number of sells
-
-71
-
Price
-
$24.25
Significant Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q3 2021
173 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2021.
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) has 145 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60,858,590 shares
of 89,414,894 outstanding shares and own 68.06% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (5,614,428 shares), ARMISTICE CAPITAL, LLC (4,748,000 shares), BlackRock Inc. (4,562,832 shares), JANUS HENDERSON GROUP PLC (4,023,074 shares), MACQUARIE GROUP LTD (3,951,841 shares), VANGUARD GROUP INC (3,865,481 shares), STATE STREET CORP (2,782,323 shares), BAKER BROS. ADVISORS LP (2,039,772 shares), PERCEPTIVE ADVISORS LLC (1,965,555 shares), and VR Adviser, LLC (1,732,410 shares).
This table shows the top 145 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.